AbbVie Inc.'s Q2 2025 results showcase Skyrizi & Rinvoq's growth, strong finances, and a promising pipeline. Click for my ...

AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people familiar with the matter, highlighting growing interest in a controversial ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie, in collaboration with REGENXBIO Inc., is ...

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus ...

Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...

AbbVie Inc. (NYSE: ABBV) stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 ...

This clinical study update could influence AbbVie’s stock performance by showcasing its commitment to innovative cancer treatments. Positive outcomes may enhance investor confidence and position ...

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 ...

Shares of AbbVie Inc. ABBV rose 1.42% to $201.47 Wednesday, on what proved to be an all-around positive trading session for ...

This was the stock's second consecutive day of gains.